SK19602000A3 - Liečivá obsahujúce bisfosfónové kyseliny a ich deriváty na profylaxiu a ošetrovanie autoimúnnych ochorení a alergií - Google Patents

Liečivá obsahujúce bisfosfónové kyseliny a ich deriváty na profylaxiu a ošetrovanie autoimúnnych ochorení a alergií Download PDF

Info

Publication number: SK19602000A3
Authority: SK; Slovakia
Prior art keywords: substituted; unsubstituted; radical; derivatives; extracts
Prior art date: 1998-06-26

Application number

SK1960-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Hassan Jomaa

Original Assignee

Hassan Jomaa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-26

Filing date

1999-06-24

Publication date

2001-07-10

1999-06-24 Application filed by Hassan Jomaa filed Critical Hassan Jomaa

2001-07-10 Publication of SK19602000A3 publication Critical patent/SK19602000A3/sk

Links

239000002253 acid Substances 0.000 title claims abstract description 42
150000007513 acids Chemical class 0.000 title claims abstract description 29
206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 25
230000007815 allergy Effects 0.000 title claims abstract description 24
208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 21
239000003814 drug Substances 0.000 title claims abstract description 13
239000013566 allergen Substances 0.000 claims abstract description 31
208000026935 allergic disease Diseases 0.000 claims abstract description 7
239000002674 ointment Substances 0.000 claims abstract description 6
239000007921 spray Substances 0.000 claims abstract description 6
206010028372 Muscular weakness Diseases 0.000 claims abstract description 4
206010046851 Uveitis Diseases 0.000 claims abstract description 4
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 4
230000036473 myasthenia Effects 0.000 claims abstract description 4
238000002360 preparation method Methods 0.000 claims abstract description 4
206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 4
206010039710 Scleroderma Diseases 0.000 claims abstract description 3
239000007787 solid Substances 0.000 claims abstract description 3
-1 heterocyclic radical Chemical class 0.000 claims description 51
239000000284 extract Substances 0.000 claims description 37
238000011282 treatment Methods 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 14
238000011321 prophylaxis Methods 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 14
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 12
210000003491 skin Anatomy 0.000 claims description 12
210000004027 cell Anatomy 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 9
150000005840 aryl radicals Chemical class 0.000 claims description 8
229910052791 calcium Inorganic materials 0.000 claims description 8
125000000524 functional group Chemical group 0.000 claims description 8
229910052782 aluminium Inorganic materials 0.000 claims description 7
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
150000001413 amino acids Chemical class 0.000 claims description 6
150000003868 ammonium compounds Chemical class 0.000 claims description 6
150000003863 ammonium salts Chemical class 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
229910052749 magnesium Inorganic materials 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000000737 periodic effect Effects 0.000 claims description 6
229910052700 potassium Inorganic materials 0.000 claims description 6
150000003254 radicals Chemical class 0.000 claims description 6
229910052708 sodium Inorganic materials 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 5
102000008186 Collagen Human genes 0.000 claims description 4
108010035532 Collagen Proteins 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 4
125000004450 alkenylene group Chemical group 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 4
230000001363 autoimmune Effects 0.000 claims description 4
229920001436 collagen Polymers 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
230000002496 gastric effect Effects 0.000 claims description 4
230000000968 intestinal effect Effects 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 4
239000002184 metal Substances 0.000 claims description 4
210000003205 muscle Anatomy 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
208000011231 Crohn disease Diseases 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 3
208000007502 anemia Diseases 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
239000002207 metabolite Substances 0.000 claims description 3
201000006417 multiple sclerosis Diseases 0.000 claims description 3
210000001519 tissue Anatomy 0.000 claims description 3
208000026872 Addison Disease Diseases 0.000 claims description 2
206010062269 Adrenalitis Diseases 0.000 claims description 2
208000004300 Atrophic Gastritis Diseases 0.000 claims description 2
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
102000014824 Crystallins Human genes 0.000 claims description 2
108010064003 Crystallins Proteins 0.000 claims description 2
208000036495 Gastritis atrophic Diseases 0.000 claims description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 2
208000000112 Myalgia Diseases 0.000 claims description 2
206010034277 Pemphigoid Diseases 0.000 claims description 2
208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
101710137302 Surface antigen S Proteins 0.000 claims description 2
210000004404 adrenal cortex Anatomy 0.000 claims description 2
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
208000016644 chronic atrophic gastritis Diseases 0.000 claims description 2
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
206010009887 colitis Diseases 0.000 claims description 2
201000001981 dermatomyositis Diseases 0.000 claims description 2
230000003394 haemopoietic effect Effects 0.000 claims description 2
208000006454 hepatitis Diseases 0.000 claims description 2
230000001900 immune effect Effects 0.000 claims description 2
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 2
229940029329 intrinsic factor Drugs 0.000 claims description 2
210000004153 islets of langerhan Anatomy 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
210000005229 liver cell Anatomy 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
210000004165 myocardium Anatomy 0.000 claims description 2
210000000653 nervous system Anatomy 0.000 claims description 2
210000001711 oxyntic cell Anatomy 0.000 claims description 2
210000003516 pericardium Anatomy 0.000 claims description 2
210000004927 skin cell Anatomy 0.000 claims description 2
108010009685 Cholinergic Receptors Proteins 0.000 claims 1
206010015943 Eye inflammation Diseases 0.000 claims 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
102000009843 Thyroglobulin Human genes 0.000 claims 1
108010034949 Thyroglobulin Proteins 0.000 claims 1
102000034337 acetylcholine receptors Human genes 0.000 claims 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
229960002175 thyroglobulin Drugs 0.000 claims 1
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract description 9
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract description 3
KBPGKWPDIYMIFV-UHFFFAOYSA-N (2-amino-2-imino-1-phosphonoethyl)phosphonic acid Chemical compound NC(=N)C(P(O)(O)=O)P(O)(O)=O KBPGKWPDIYMIFV-UHFFFAOYSA-N 0.000 abstract description 2
NHAOLKGXQFICNN-UHFFFAOYSA-N (amino-hydroxy-phosphonomethyl)phosphonic acid Chemical compound OP(=O)(O)C(O)(N)P(O)(O)=O NHAOLKGXQFICNN-UHFFFAOYSA-N 0.000 abstract description 2
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract description 2
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract description 2
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract description 2
229960004343 alendronic acid Drugs 0.000 abstract description 2
229960005236 ibandronic acid Drugs 0.000 abstract description 2
229950006971 incadronic acid Drugs 0.000 abstract description 2
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract description 2
229960003978 pamidronic acid Drugs 0.000 abstract description 2
229960000759 risedronic acid Drugs 0.000 abstract description 2
229960005324 tiludronic acid Drugs 0.000 abstract description 2
229960004276 zoledronic acid Drugs 0.000 abstract description 2
XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 abstract description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 26
229940122361 Bisphosphonate Drugs 0.000 description 15
239000004480 active ingredient Substances 0.000 description 13
235000019359 magnesium stearate Nutrition 0.000 description 13
241000283690 Bos taurus Species 0.000 description 9
102000000503 Collagen Type II Human genes 0.000 description 9
108010041390 Collagen Type II Proteins 0.000 description 9
239000000126 substance Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
229910019142 PO4 Inorganic materials 0.000 description 8
229920002472 Starch Polymers 0.000 description 8
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
239000010452 phosphate Substances 0.000 description 8
239000008107 starch Substances 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
229930195725 Mannitol Natural products 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000000594 mannitol Substances 0.000 description 7
235000010355 mannitol Nutrition 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000012050 conventional carrier Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008187 granular material Substances 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000011575 calcium Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000008298 dragée Substances 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000000034 method Methods 0.000 description 4
239000006187 pill Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
108010010974 Proteolipids Proteins 0.000 description 3
102000016202 Proteolipids Human genes 0.000 description 3
239000013543 active substance Substances 0.000 description 3
150000004663 bisphosphonates Chemical class 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
235000010419 agar Nutrition 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229960003444 immunosuppressant agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
239000001993 wax Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
206010063655 Erosive oesophagitis Diseases 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010022004 Influenza like illness Diseases 0.000 description 1
206010025327 Lymphopenia Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010030201 Oesophageal ulcer Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
201000011152 Pemphigus Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
230000010757 Reduction Activity Effects 0.000 description 1
KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940062527 alendronate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
239000000427 antigen Substances 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000002639 bone cement Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000004665 defense response Effects 0.000 description 1
239000007950 delayed release tablet Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
239000003221 ear drop Substances 0.000 description 1
229940047652 ear drops Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
229940093499 ethyl acetate Drugs 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
SZMNOLSLNRNAJC-UHFFFAOYSA-N formaldehyde;propane-1,2,3-triol Chemical compound O=C.OCC(O)CO SZMNOLSLNRNAJC-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000003906 humectant Substances 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
231100001023 lymphopenia Toxicity 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000003158 microbiostatic effect Effects 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000004044 response Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SK1960-2000A 1998-06-26 1999-06-24 Liečivá obsahujúce bisfosfónové kyseliny a ich deriváty na profylaxiu a ošetrovanie autoimúnnych ochorení a alergií SK19602000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19828450A DE19828450A1 (de)	1998-06-26	1998-06-26	Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
PCT/DE1999/001844 WO2000000182A2 (de)	1998-06-26	1999-06-24	Bisphosphonsäuren und deren derivate enthaltende arzneimittel zur prophylaxe und zur behandlung von autoimmunkrankheiten sowie von allergien

Publications (1)

Publication Number	Publication Date
SK19602000A3 true SK19602000A3 (sk)	2001-07-10

Family

ID=7872064

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1960-2000A SK19602000A3 (sk)	1998-06-26	1999-06-24	Liečivá obsahujúce bisfosfónové kyseliny a ich deriváty na profylaxiu a ošetrovanie autoimúnnych ochorení a alergií

Country Status (24)

Country	Link
EP (1)	EP1089761B1 (es)
JP (1)	JP2002519319A (es)
KR (1)	KR20010053211A (es)
AT (1)	ATE224734T1 (es)
AU (1)	AU740605B2 (es)
CA (1)	CA2334711C (es)
DE (2)	DE19828450A1 (es)
DK (1)	DK1089761T3 (es)
EA (1)	EA200100080A1 (es)
EE (1)	EE200000756A (es)
ES (1)	ES2184496T3 (es)
HR (1)	HRP20000820A2 (es)
HU (1)	HUP0102873A3 (es)
ID (1)	ID27515A (es)
IL (1)	IL139966A0 (es)
IS (1)	IS5748A (es)
MX (1)	MXPA00012338A (es)
NO (1)	NO20006572L (es)
NZ (1)	NZ509505A (es)
PL (1)	PL345287A1 (es)
PT (1)	PT1089761E (es)
SK (1)	SK19602000A3 (es)
TR (1)	TR200003821T2 (es)
WO (1)	WO2000000182A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1331597A (zh)	1998-12-23	2002-01-16	朱马制药有限公司	双膦酸酯用于预防和治疗传染性病变的用途
EP1057488A4 (en) *	1998-12-25	2003-10-22	Toray Industries	INTERLEUKIN-6 PRODUCTION INHIBITORS
PT1392325E (pt) *	2001-05-02	2006-10-31	Novartis Ag	Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
WO2003009855A2 (de)	2001-07-20	2003-02-06	Bioagency Ag	Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
GB0307989D0 (en) *	2003-04-07	2003-05-14	Mcewen Lab Ltd	Therapeutic composition
EP1930011B1 (en) *	2004-08-23	2011-08-17	Teva Pharmaceutical Industries Ltd	Crystalline form of ibandronate sodium
CN101262856A (zh) *	2005-09-12	2008-09-10	雷迪博士实验室有限公司	唑来膦酸的结晶三水合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2114946T3 (es) *	1991-09-05	1998-06-16	Toray Industries	Derivado de acido metanodifosfonico, su produccion y uso medicinal.
JP4231106B2 (ja) *	1995-01-23	2009-02-25	ゼノテックインコーポレイティッド	骨溶解および転移を改善する方法

1998
- 1998-06-26 DE DE19828450A patent/DE19828450A1/de not_active Withdrawn
1999
- 1999-06-24 EE EEP200000756A patent/EE200000756A/xx unknown
- 1999-06-24 IL IL13996699A patent/IL139966A0/xx unknown
- 1999-06-24 PT PT99941383T patent/PT1089761E/pt unknown
- 1999-06-24 KR KR1020007014813A patent/KR20010053211A/ko not_active Ceased
- 1999-06-24 JP JP2000556767A patent/JP2002519319A/ja active Pending
- 1999-06-24 SK SK1960-2000A patent/SK19602000A3/sk unknown
- 1999-06-24 EA EA200100080A patent/EA200100080A1/ru unknown
- 1999-06-24 ID IDW20002676A patent/ID27515A/id unknown
- 1999-06-24 PL PL99345287A patent/PL345287A1/xx unknown
- 1999-06-24 HR HR20000820A patent/HRP20000820A2/hr not_active Application Discontinuation
- 1999-06-24 TR TR2000/03821T patent/TR200003821T2/xx unknown
- 1999-06-24 ES ES99941383T patent/ES2184496T3/es not_active Expired - Lifetime
- 1999-06-24 NZ NZ509505A patent/NZ509505A/xx not_active IP Right Cessation
- 1999-06-24 DK DK99941383T patent/DK1089761T3/da active
- 1999-06-24 HU HU0102873A patent/HUP0102873A3/hu unknown
- 1999-06-24 DE DE59902856T patent/DE59902856D1/de not_active Expired - Lifetime
- 1999-06-24 MX MXPA00012338A patent/MXPA00012338A/es unknown
- 1999-06-24 EP EP99941383A patent/EP1089761B1/de not_active Expired - Lifetime
- 1999-06-24 AU AU55033/99A patent/AU740605B2/en not_active Ceased
- 1999-06-24 WO PCT/DE1999/001844 patent/WO2000000182A2/de not_active Ceased
- 1999-06-24 CA CA002334711A patent/CA2334711C/en not_active Expired - Fee Related
- 1999-06-24 AT AT99941383T patent/ATE224734T1/de active
2000
- 2000-12-01 IS IS5748A patent/IS5748A/is unknown
- 2000-12-21 NO NO20006572A patent/NO20006572L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20006572D0 (no)	2000-12-21
PT1089761E (pt)	2003-02-28
NZ509505A (en)	2002-11-26
EA200100080A1 (ru)	2001-06-25
EP1089761B1 (de)	2002-09-25
HRP20000820A2 (en)	2001-12-31
HUP0102873A3 (en)	2002-04-29
JP2002519319A (ja)	2002-07-02
DE19828450A1 (de)	1999-12-30
NO20006572L (no)	2001-02-21
DE59902856D1 (de)	2002-10-31
AU740605B2 (en)	2001-11-08
WO2000000182A2 (de)	2000-01-06
IL139966A0 (en)	2002-02-10
CA2334711C (en)	2006-12-05
DK1089761T3 (da)	2003-02-03
TR200003821T2 (tr)	2001-06-21
PL345287A1 (en)	2001-12-03
WO2000000182A3 (de)	2000-03-30
ID27515A (id)	2001-04-12
KR20010053211A (ko)	2001-06-25
EE200000756A (et)	2002-04-15
ATE224734T1 (de)	2002-10-15
CA2334711A1 (en)	2000-01-06
HUP0102873A2 (hu)	2001-12-28
MXPA00012338A (es)	2003-04-25
EP1089761A2 (de)	2001-04-11
ES2184496T3 (es)	2003-04-01
IS5748A (is)	2000-12-01
AU5503399A (en)	2000-01-17

Publication	Publication Date	Title
US9169279B2 (en)	2015-10-27	Crystallization method and bioavailability
CA2410201C (en)	2010-10-26	Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP2531200B1 (en)	2017-07-12	Crystallization method and bioavailability
RU2329809C2 (ru)	2008-07-27	Применения бисфосфоновых кислот для лечения и профилактики остеопороза
CZ297341B6 (cs)	2006-11-15	Potazená perorální tableta pro lécbu kostních onemocnení obsahující jako úcinnou látku ibandronát
WO2003009855A2 (de)	2003-02-06	Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
WO2008069652A1 (en)	2008-06-12	Combinations of a sphingolipid and an hmg-coa reductase inhibitor for treating hypercholesterolemia
SK19602000A3 (sk)	2001-07-10	Liečivá obsahujúce bisfosfónové kyseliny a ich deriváty na profylaxiu a ošetrovanie autoimúnnych ochorení a alergií
EP2438076B1 (en)	2018-12-19	Targeted drug delivery to the bone
EP1140113B1 (de)	2003-11-05	Verwendung von bisphosphonaten zur prophylaxe und zur behandlung von infektiösen prozessen
US20170022227A1 (en)	2017-01-26	Crystallization method and bioavailability
CZ139395A3 (en)	1996-01-17	The use of 4-chloro-5-/(4,5-dihydro-1h-imidazol-2-yl)-amino/-6-methoxy-2-methylpyridine and anti-hyperglycaemically active pharmaceutical composition
EP0762883B1 (en)	2001-11-14	Pyridylbisphosphonates for use as a therapeutical agent
SK8612002A3 (en)	2003-03-04	Compositions and methods for L-nucleosides, L-nucleotides, and their analogs
EP0104826A2 (en)	1984-04-04	Immunomodulator and method of use for immunomodulation
RU2001111816A (ru)	2003-09-27	Соединенные с желчными кислотами производные пропаноламина для лечения нарушений липидного обмена
CZ20004762A3 (cs)	2001-04-11	Bisfosfonové kyseliny a jejich deriváty obsahující léčiva pro profylaxi a ošetřování autoimunitních chorob i alergií
US20060040899A1 (en)	2006-02-23	Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
EP1591122A1 (en)	2005-11-02	Method of administering bisphosphonates
SK278918B6 (sk)	1998-04-08	Farmaceutický prostriedok proti vysokému krvnému t
CA2352511A1 (en)	2000-06-02	Use of phosphonoformic acid derivatives for treating infections
US3296074A (en)	1967-01-03	Methods and compositions for treating psychoses and neuroses
JPH0374330A (ja)	1991-03-28	脱髄疾患治療剤
CS209860B2 (cs)	1981-12-31	Způsob výroby nových derivátů aminokyselin
EP0981351A1 (de)	2000-03-01	Verwendung von diphosphonsäuren oder deren physiologisch verträglichen salzen oder estern zur präventiven behandlung von spätfolgen bei harnblasenerweiterung oder harnblasenersatz